Parallax Volatility Advisers
CNCE

Parallax Volatility Advisers’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Parallax Volatility Advisers’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-3,687
Closed -$95K – 4695
2017
Q4 		$95K Buy
+3,687
New +$74.2K ﹤0.01% 2840

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Parallax Volatility Advisers's CNCE Position: Q1 2018 in Review

Parallax Volatility Advisers sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2018, closing a stake of 3,687 shares — an estimated $95K sold.

Parallax Volatility Advisers first reported a position in CNCE in Q4 2017 and held it in 1 quarter. The position peaked at $95K in Q4 2017. 123 funds tracked by Wall St. Rank hold CNCE as of Q1 2018.

  • Parallax Volatility Advisers reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 3,687 Concert Pharmaceuticals, Inc. shares in Q1 2018, an estimated $95K.
  • Parallax Volatility Advisers first reported a position in Concert Pharmaceuticals, Inc. in Q4 2017 and held it in 1 quarter.
  • Parallax Volatility Advisers's Concert Pharmaceuticals, Inc. position peaked at $95K in Q4 2017.
  • 123 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2018.

Based on Parallax Volatility Advisers's 13F filing for Q1 2018, filed 15 May 2018.